Last reviewed · How we verify
glutamate and aspartate
At a glance
| Generic name | glutamate and aspartate |
|---|---|
| Sponsor | University Hospital, Caen |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Dietary Intervention for Migraine Relief (NA)
- Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder (PHASE1)
- Prandial Metabolic Phenotype in Adults (NA)
- Role Of Ketamine in Treatment-Resistant Major Depressive Disorder And Its Effect on Suicidality (NA)
- Effect of Intravenous Nalbuphine and Magnesium Sulfate on Emergence Agitation in Pediatric (PHASE3)
- Efficacy of Ketamine Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus (PHASE2, PHASE3)
- Excitotoxicity Markers and the Clinical-radiological Progression After a Demyelinating Event: a Prospective Pilot Study (NA)
- Ketamine for Depression and Alcohol Dependence (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- glutamate and aspartate CI brief — competitive landscape report
- glutamate and aspartate updates RSS · CI watch RSS
- University Hospital, Caen portfolio CI